Direct-to-consumer company tests FDA's resolve on gene testing
Monday, November 9, 2015 - 04:25
in Biology & Nature
CHICAGO (Reuters) - Just as 23andMe has made peace with the U.S. Food and Drug Administration, another direct-to-consumer genetics company is testing the regulatory waters with the launch of a $249 DNA test designed to predict drug response.